U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07109414) titled 'Trial of NP-G2-044 Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer' on July 31.
Brief Summary: The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs. PLD alone in participants with platinum-resistant ovarian cancer (PROC).
Study Start Date: Aug. 15
Study Type: INTERVENTIONAL
Condition:
Platinum-resistant Ovarian Cancer
Intervention:
DRUG: NP-G2-044
NP-G2-044 will be provided as a tablet via oral route of administration in the study.
DRUG: PLD
P...